A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma

Trial Profile

A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 26 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Dec 2014 Planned End Date changed from 1 Sep 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 28 Aug 2014 Planned primary completion date changed to 1 May 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top